Cetuximab FLEXes muscle in first-line advanced NSCLC

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1641, 2008-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cisplatin + pemetrexed as first-line therapy for advanced NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Docetaxel: clinical benefit in first-line treatment for NSCLC

Inpharma, Vol. 1, Iss. 1348, 2002-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Irinotecan plus docetaxel a first-line option for NSCLC

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

By Ko Andrew

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1597-1606

Springer Publishing Company

Access to resources Recommend Favorite

First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer

By Gill S.

Drugs, Vol. 64, Iss. 1, 2004-01 ,pp. : 27-44

Adis International

Access to resources Recommend Favorite